August 15, 2022

Novel Oral SIK Inhibitors for Musculoskeletal Diseases Licensed to Radius Health

Marc Wein, MD, PhD, 2018 Harrington Scholar-Innovator, is an investigator in the Massachusetts General Hospital Endocrine Unit with a clinical focus on osteoporosis and metabolic bone diseases. He recently licensed the IP for novel orally-available salt inducible kinase (SIK) inhibitors, developed in large part with Harrington Discovery Institute, to Radius Health. Dr. Wein's team, including collaborators at the Dana-Farber Cancer Institute and the Broad Institute, found that a small molecule SIK inhibitor, YKL-05-099, builds new bone by mimicking the side effects of a parathyroid hormone.

This license agreement will facilitate future development of SIK inhibitors for osteoporosis and other indications. In addition to the license contract, Dr. Wein will continue to collaborate with Radius during the 'lead optimization' phase of his project.

"Oral bone building medications for osteoporosis remain a major unmet medical need. This is a perfect opportunity to move discoveries from the laboratory towards patients. I'm thrilled about this news, and am extremely grateful to Harrington Discovery Institute for all the support that led to this major project milestone."

- Marc Wein, MD, PhD

Click here to read the full article on Radius Health

About the Scholar

Endocrine, Musculoskeletal

Marc Wein, MD, PhD

Massachusetts General Hospital
Harrington Scholar-Innovator

More about Marc Wein